Profiles Header - Harvard Catalyst Profiles Header – Harvard Catalyst

Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Carmelo Nucera, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Overview
2018 Van Meter Award "Drug resistance and iodine metabolism in BRAFV600E thyroid cancer” to Carmelo Nucera, MD, PhD

The Van Meter Award recognizes outstanding contributions to research on the thyroid gland or related subjects by an investigator who is age 45 or under. Dr. Nucera has given the prestigious Van Meter Lecture on October 4 at 8:05 am, during this year’s ATA Annual Meeting in Washington, DC from October 3 to 7 2018. The award winner and the title of his lecture are kept secret until the time of the presentation

"Human Thyroid Cancers Preclinical and Translational Research" is open to accept medical students, PhD students, experienced basic researcher, as well as international PhD students, in order to be mentored from me on different advanced research projects on human thyroid cancers and BRAFV600E.

Young and experienced PhD basic researchers are also encouraged to apply to be mentored in angiogenesis/inflammation program related to thyroid diseases.

I'm an Assistant Professor at Harvard Medical School in the field of Thyroid Cancer, and I was recently awarded from the American Thyroid Association and from the NIH/NCI for Thyroid Cancer Research and BRAFV600E.
I'm developing my own independent research program in the "Division of Cancer Biology and Angiogenesis" at the BIDMC/HMS, focused on "preclinical models of human thyroid cancer with an emphasis on mechanisms of metastatic networks, new models of in vitro angiogenesis, tumor microenvironment, and metabolic regulations, using and dissecting new targeted therapies anti-BRAFV600E (e.g. Vemurafenib/PLX4032, Sorafenib, etc.)".
In particular, my research interests are in elucidating mechanisms by which the oncogene BRAFV600E leads to the invasive behavior in aggressive, metastatic, and iodine-refractory thyroid cancers.
I'm highly committed to applying my research to patient care, to facilitate innovation to solve unmet clinical needs, and improve public health.
I'm genuinely dedicated to advancing translational Thyroid Cancer Research.

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA181183 (NUCERA, CARMELO) Jul 1, 2014 - May 31, 2019
    NIH/NCI
    BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression
    Role: Principal Investigator
  2. R21CA165039 (NUCERA, CARMELO) Jul 6, 2012 - Jun 30, 2014
    NIH/NCI
    Metastatic protein network in BRAFV600E positive human thyroid cancers
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Prete A, Lo AS, Sadow PM, Bhasin SS, Antonello ZA, Vodopivec DM, Ullas S, Sims JN, Clohessy J, Dvorak AM, Sciuto T, Bhasin M, Murphy-Ullrich JE, Lawler J, Karumanchi SA, Nucera C. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFß1 Axis. Clin Cancer Res. 2018 Aug 03. PMID: 30076136.
    View in: PubMed
  2. Antonello ZA, Hsu N, Bhasin M, Roti G, Joshi M, Van Hummelen P, Ye E, Lo AS, Karumanchi SA, Bryke CR, Nucera C. Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E. Oncotarget. 2017 Oct 17; 8(49):84743-84760. PMID: 29156680.
    View in: PubMed
  3. Mehrzad R, Nishino M, Nucera C, Dias-Santagata D, Hennessey JV, Hasselgren PO. Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasis-A case report. Int J Surg Case Rep. 2017; 38:180-184. PMID: 28780248.
    View in: PubMed
  4. Daniell K, Nucera C. Effect of the micronutrient iodine in thyroid carcinoma angiogenesis. Aging (Albany NY). 2016 12 20; 8(12):3180-3184. PMID: 27997357.
    View in: PubMed
  5. Nucera C. Evolution of resistance to thyroid cancer therapy. Aging (Albany NY). 2016 08; 8(8):1576-7. PMID: 27575377.
    View in: PubMed
  6. Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget. 2015 Dec 15; 6(40):42445-67. PMID: 26636651; PMCID: PMC4767444.
  7. Sadow PM, Dias-Santagata D, Zheng Z, Lin DT, Le LP, Nucera C. Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis. Endocr Relat Cancer. 2015 Dec; 22(6):L23-8. PMID: 26472209; PMCID: PMC4609031 [Available on 12/01/16].
  8. Husain A, Hu N, Sadow PM, Nucera C. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E). Cancer Lett. 2016 10 01; 380(2):577-85. PMID: 26189429; PMCID: PMC4715997 [Available on 10/01/17].
  9. Kovach AE, Nucera C, Lam QT, Nguyen A, Dias-Santagata D, Sadow PM. Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker. Discoveries (Craiova). 2015 Apr-Jun; 3(2). PMID: 26317117.
    View in: PubMed
  10. Smith N, Nucera C. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab. 2015 Jan; 100(1):35-42. PMID: 25347569; PMCID: PMC4283016.
  11. Sadow PM, Priolo C, Nanni S, Karreth FA, Duquette M, Martinelli R, Husain A, Clohessy J, Kutzner H, Mentzel T, Carman CV, Farsetti A, Henske EP, Palescandolo E, Macconaill LE, Chung S, Fadda G, Lombardi CP, De Angelis AM, Durante O, Parker JA, Pontecorvi A, Dvorak HF, Fletcher C, Pandolfi PP, Lawler J, Nucera C. Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. J Natl Cancer Inst. 2014 Aug; 106(8). PMID: 25063326; PMCID: PMC4155429.
  12. Antonello ZA, Nucera C. Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene. 2014 Nov 20; 33(47):5397-404. PMID: 24362526; PMCID: PMC4524291.
  13. Duquette M, Sadow PM, Lawler J, Nucera C. Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Front Endocrinol (Lausanne). 2013; 4:189. PMID: 24348463; PMCID: PMC3845490.
  14. Nucera C. Targeting thyroid cancer microenvironment: basic research and clinical applications. Front Endocrinol (Lausanne). 2013; 4:167. PMID: 24204363; PMCID: PMC3816219.
  15. Bellelli R, Castellone MD, Garcia-Rostan G, Ugolini C, Nucera C, Sadow PM, Nappi TC, Salerno P, Cantisani MC, Basolo F, Gago TA, Salvatore G, Santoro M. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr Relat Cancer. 2012 Oct; 19(5):695-710. PMID: 22919068; PMCID: PMC3637951.
  16. Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, Harris L, Wan L, Fukushima H, Husain A, Nose V, Fadda G, Sadow PM, Goessling W, North T, Lawler J, Wei W. SCF(ß-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med. 2012 Jul 02; 209(7):1289-307. PMID: 22711876; PMCID: PMC3405505.
  17. Nucera C, Pontecorvi A. Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? Front Endocrinol (Lausanne). 2012; 3:33. PMID: 22649416; PMCID: PMC3355963.
  18. Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, Parangi S. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology. 2012 Feb; 153(2):985-94. PMID: 22202162; PMCID: PMC3275388.
  19. Nucera C, Lawler J, Parangi S. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res. 2011 Apr 01; 71(7):2417-22. PMID: 21447745; PMCID: PMC3913061.
  20. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011; 16(3):296-309. PMID: 21355020; PMCID: PMC3073446.
  21. Nehs MA, Nagarkatti S, Nucera C, Hodin RA, Parangi S. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery. 2010 Dec; 148(6):1154-62; discussion 1162. PMID: 21134546; PMCID: PMC3413092.
  22. Nucera C, Lawler J, Hodin R, Parangi S. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget. 2010 Dec; 1(8):751-6. PMID: 21321384; PMCID: PMC3074562.
  23. Nucera C, Muzzi P, Tiveron C, Farsetti A, La Regina F, Foglio B, Shih SC, Moretti F, Della Pietra L, Mancini F, Sacchi A, Trimarchi F, Vercelli A, Pontecorvi A. Maternal thyroid hormones are transcriptionally active during embryo-foetal development: results from a novel transgenic mouse model. J Cell Mol Med. 2010 Oct; 14(10):2417-35. PMID: 19863697; PMCID: PMC3823160.
  24. Mekel M, Nucera C, Hodin RA, Parangi S. Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg. 2010 Jul; 200(1):136-43. PMID: 20637346; PMCID: PMC3880203.
  25. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A. 2010 Jun 08; 107(23):10649-54. PMID: 20498063; PMCID: PMC2890809.
  26. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905. PMID: 20164920; PMCID: PMC2826709.
  27. Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, Parangi S. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid. 2009 Oct; 19(10):1077-84. PMID: 19772429; PMCID: PMC2833178.
  28. Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M, Brown M. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3680-9. PMID: 19470727.
    View in: PubMed
  29. Nucera C, Goldfarb M, Hodin R, Parangi S. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta. 2009 Apr; 1795(2):152-61. PMID: 19356676; PMCID: PMC3814130.
  30. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008 Mar; 15(1):191-205. PMID: 18310287.
    View in: PubMed
  31. Nucera C, Vaccaro M, Moleti M, Priolo C, Tortorella G, Angioni A, Ientile R, Violi MA, Loda M, Trimarchi F, Vermiglio F. antiphospholipid antibodies syndrome associated with hyperhomocysteinemia related to MTHFR Gene C677T and A1298C heterozygous mutations in a young man with idiopathic hypoparathyroidism (DiGeorge syndrome). J Clin Endocrinol Metab. 2006 Jun; 91(6):2021-6. PMID: 16595601.
    View in: PubMed
  32. Nucera C, Mazzon E, Caillou B, Violi MA, Moleti M, Priolo C, Sturniolo G, Puzzolo D, Cavallari V, Trimarchi F, Vermiglio F. Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia. J Endocrinol Invest. 2005 Feb; 28(2):106-12. PMID: 15887854.
    View in: PubMed
  33. Moleti M, Mattina F, Salamone I, Violi MA, Nucera C, Baldari S, Lo Schiavo MG, Regalbuto C, Trimarchi F, Vermiglio F. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy. Thyroid. 2003 Jul; 13(7):653-8. PMID: 12964971.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Nucera's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (189)
Explore
_
Co-Authors (53)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Tool Page Footer - Harvard Catalyst Tool Page Footer – Harvard Catalyst
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.